The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding

摘要: Background Coagulopathy related to massive bleeding has a multifactorial aetiology. Coagulopathy is shock and blood loss including consumption of clotting factors platelets hemodilution. Additionally hyperfibrinolysis, hypothermia, acidosis, metabolic changes affect the coagulation system. The aim any hemostatic therapy control minimize transfusion requirements. Transfusion allogeneic products as well presence coagulopathy cause increased morbidity mortality. Study Design Methods This paper presents short review on new treatment strategies coagulopathy, loss. Results Paradigms are actively changing there still shortage data. However, increasing experience evidence that “target controlled algorithms” using point-of-care monitoring devices factor concentrates more effective compared fresh frozen plasma, independently individual clinical situation. Conclusion Future associated with can be based an individualized guided rational use such fibrinogen, prothrombin complex concentrate, recombinant VIIa. timely may efficacious safer than ratio-driven packages products.